CheckMate-142: Updated data from MSI high metastatic colon cancer patients

Bookmark and Share
Published: 13 Jun 2019
Views: 739
Rating:
Save
Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

Prof Heinz-Josef Lenz talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the updated results from a study he presented at ESMO 2018.

The MSI high metastatic colon cancer patients report an improved efficacy, and at 15 months over 80% have not progressed with a low toxicity profile.